What is the antidote for a patient with severe cytokine release syndrome (CRS) after treatment with CAR-T?
Tocilizumab. It is a humanized monoclonal antibody that competitively inhibits binding of IL-6 to its receptor. It is indicated for any CRS grade above 2. CARTOX is a phone app developed by MD Anderson Cancer Center which allows easy determination of grading criteria and management options.
Lipe DM and Shafer S. CAR-T and checkpoint inhibitors: toxicities and antidotes in the emergency department. Clin Tox 2021; Ahead of print: 1-17. https://doi.org/10.1080/15563650.2021.1880008
Posted in Question Of The Day